Dolutegravir Sodium/Emtricitabine/Tenofovir Alafenamide

多替拉韦钠/恩曲他滨/艾酚福韦

Report date: 2022/12/07 18:09:28
NME

Base Information

Drug NameDolutegravir Sodium/Emtricitabine/Tenofovir Alafenamide
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHIV integrase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseHuman immunodeficiency virus type 1 reverse transcriptaseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Dolutegravir SodiumEmtricitabine
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A